Trial reportScientific reports2026
Utility and safety of a self-developed patent chest strap in endoscopic transaxillary thyroid surgery: a prospective comparative effectiveness study.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A novel patent chest-strap was developed for use in endoscopic transaxillary thyroid surgery. We conducted a phase prospective study in China to evaluate its utility and safety. This phase 1 study evaluates the utility, safety, and effectiveness of a novel patent chest-strap in a real-world clinical patient population. This single-center, open-label, prospective, randomized study was conducted from July 1, 2025, to March 31, 2026, to evaluate the long-term safety and efficacy of a patented chest strap (PCS) in patients undergoing endoscopic transaxillary thyroidectomy. Patients older than 18 years who underwent the procedure with or without the chest strap were enrolled. The primary endpoints included postoperative drainage outcomes and total usage of the PCS, which served as measures of effectiveness. Secondary endpoints focused on strap-related complaints, assessed in comparison with traditional bandages (TB), to evaluate safety. A total of 108 patients were included in the PCS group and 126 in the TB group. In the PCS group, the mean age was 43.5 ± 16.2 years, and 61 patients (56.48%) were female. Compared with the TB group, the PCS group showed statistically significant differences in height (1.67 ± 0.03 m vs. 1.73 ± 0.04 m; P < 0.00001), weight, and body mass index (P < 0.0001). The mean postoperative drainage volume on the first day was 50 mL in the PCS group and 48.5 ± 9.19 mL in the TB group. Drainage volumes differed significantly between groups on the second day (36 ± 8.49 mL vs. 44 ± 12.73 mL; P < 0.001) and the third day (35 ± 7.07 mL vs. 25 mL; P < 0.001). The total postoperative drainage volume was lower in the PCS group than in the TB group (111.92 ± 13.44 mL vs. 122.5 ± 24.75 mL). Complications were more frequent in the TB group. Skin allergy occurred in 40 patients (31.75%) in the TB group compared with 9 patients (8.33%) in the PCS group. The patent chest-strap has the postoperative benefits for patients with endoscopic transanxillary thyroidectomy, and suffered fewer ratio of complications. This phase real-world study performed a positive feedback for a self-developed clinical patent transformation achievement in China.Registration: Chinese Clinical Trial Registry ( https://www.medicalresearch.org.cn/ ) ChiCTR2500107867 (Registered data: 15 August, 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.